Document Detail

Haemodynamic effects of dopexamine on postprandial splanchnic hyperaemia.
MedLine Citation:
PMID:  15086358     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The synthetic beta(2)-adrenergic and dopaminergic agonist dopexamine is supposed to prevent splanchnic hypoperfusion in critically ill patients, thus potentially interacting with haemodynamic effects of early enteral nutrition. However, precise mechanism of action and interaction with postprandial splanchnic hyperaemia of the drug are largely unknown, even in healthy subjects. MATERIALS AND METHODS: Twelve healthy volunteers received dopexamine 1 microg x kg(-1) min(-1) and dopexamine and placebo (NaCl 0.9%) 3 microg x kg(-1) min(-1) in a randomized, double-blinded order (crossover-design). Splanchnic (Doppler ultrasound) and systemic (noninvasive cardiac monitoring) haemodynamic parameters were assessed at baseline and during infusion (fasted as well as 15, 30, 45 and 60 min after a standard liquid meal). RESULTS: In fasted humans, dopexamine enhanced time-averaged maximum velocity (TAMX) in the superior mesenteric artery (1 microg + 40%; 3 microg + 82%, P < 0.05), portal vein (+ 63%; + 121%, P < 0.05) and femoral artery (+ 66%; + 87%, P < 0.05), in proportion to the increase of cardiac index (+ 33%; + 77%, both P < 0.05). In the postprandial state, TAMX rose significantly in the superior mesenteric artery (+ 139%) and portal vein (+ 68%) in the placebo group, showing the same absolute extent as dopexamine. The physiological postprandial buffer response of hepatic artery was conserved under all conditions. CONCLUSIONS: Continuous infusion of dopexamine enhances mesenterial and portal perfusion in a dose-dependent manner without affecting the extent of physiological postprandial hyperaemia. Thus, dopexamine and enteral nutrition may interact with splanchnic haemodynamics by different pathways.
S Bartsch; A Brüning; F M Reimann; D Ludwig
Related Documents :
3934908 - Myelofibrosis, splenomegaly, and portal hypertension.
14563428 - Early development of cavernomatous vasculatures in portal venous thrombosis: morphometr...
307508 - Comparison of barium swallow and left gastric angiography in the diagnosis of esophagea...
2169828 - Treatment of hepatocellular carcinoma by segmental hepatic artery injection of adriamyc...
22252328 - Aortic intramural hematoma presenting as paraplegia progressed into segmental aortic di...
22929168 - Contemporary incidence and risk factors for carotid artery disease in patients referred...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  European journal of clinical investigation     Volume:  34     ISSN:  0014-2972     ISO Abbreviation:  Eur. J. Clin. Invest.     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-04-16     Completed Date:  2004-07-20     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0245331     Medline TA:  Eur J Clin Invest     Country:  England    
Other Details:
Languages:  eng     Pagination:  268-74     Citation Subset:  IM    
University Clinics of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abdomen / ultrasonography
Adrenergic beta-Agonists / therapeutic use*
Blood Flow Velocity / drug effects
Blood Pressure / drug effects
Dopamine / analogs & derivatives*,  therapeutic use*
Dopamine Agonists / therapeutic use*
Double-Blind Method
Femoral Artery / physiopathology
Hemodynamics / drug effects*
Hepatic Artery / physiopathology
Hyperemia / prevention & control*,  ultrasonography
Mesenteric Arteries / physiopathology
Middle Aged
Portal Vein / physiopathology
Postprandial Period
Vascular Resistance / drug effects
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Dopamine Agonists; 86197-47-9/dopexamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New model for kinetic studies of HDL metabolism in humans.
Next Document:  Rat duodenal IRP1 activity and iron absorption in iron deficiency and after HO perfusion.